窄谱激酶抑制剂有望治疗干眼病及其他眼部炎症性疾病
研究从干眼病患者眼表获取结膜上皮细胞,发现p38α、Syk、Src、Lck及多种炎症因子表达显著升高;窄谱激酶抑制剂TOP1362可强效抑制这些激酶、降低炎症因子释放,并在内毒素诱导葡萄膜炎大鼠模型中剂量依赖性减轻炎症细胞浸润和眼部细胞因子水平,疗效与地塞米松相当。
要点
- 干眼病患者结膜上皮细胞中p38α、Syk、Src、Lck及IL-1β、IL-8、MCP-1、MMP-9表达显著升高。
- TOP1362强效抑制p38α、Syk、Src、Lck,并阻断高渗条件下p38α表达升高。
- 内毒素诱导葡萄膜炎大鼠模型中,TOP1362局部给药剂量依赖性减轻炎症,疗效与地塞米松相当。
核心结论
- TOP1362是干眼病中上调激酶的有效抑制剂,在体外和体内均显著减弱促炎细胞因子释放,突显窄谱激酶抑制剂治疗眼部炎症(如干眼病中所见)的治疗潜力。
研究设计与样本
- 从受试者经印迹细胞学获取人结膜上皮细胞,比较干眼病患者与健康对照的基因表达。
- 采用实时定量PCR检测人结膜上皮细胞中窄谱激酶抑制剂靶激酶及促炎细胞因子基因表达,并检测高渗处理Chang结膜上皮细胞中p38α表达。
- 通过ATP依赖性Z-LYTE和竞争结合试验评估TOP1362与激酶的相互作用,在人外周血单核细胞和原代巨噬细胞中评估抗炎活性。
- 在内毒素诱导葡萄膜炎研究中,向Lewis大鼠玻璃体内注射脂多糖,局部给予TOP1362、地塞米松或溶媒,注射后6小时测定炎症细胞因子水平。
主要发现
- 干眼病患者人结膜上皮细胞中p38α、脾酪氨酸激酶(Syk)、Src、淋巴细胞特异性蛋白酪氨酸激酶(Lck)、白细胞介素1β(IL-1β)、白细胞介素8(IL-8)、单核细胞趋化蛋白-1(MCP-1)和基质金属蛋白酶-9(MMP-9)表达显著增加。
- TOP1362强效抑制激酶靶点p38α、Syk、Src和Lck,阻断高渗Chang细胞中p38α表达升高,并在固有免疫和适应性免疫细胞模型中强效减少炎症细胞因子释放。
- 在内毒素诱导葡萄膜炎模型中,TOP1362剂量依赖性减弱脂多糖诱导的炎症细胞浸润和眼部细胞因子水平升高,疗效与地塞米松相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study is to determine the potential of narrow spectrum kinase inhibitors (NSKIs) to treat inflammatory eye disorders. METHODS: Human conjunctival epithelial (HCE) cells were retrieved from subjects via impression cytology. Real-time quantitative PCR (qPCR) was performed on HCE cells to determine gene expression of NSKI kinase targets and proinflammatory cytokines in dry eye disease (DED) patients versus healthy controls. qPCR also assessed p38α expression in hyperosmolar-treated Chang conjunctival epithelial cells. Interaction of NSKI TOP1362 with the kinases was evaluated in ATP-dependent Z-LYTE and competition binding assays. Anti-inflammatory activity was assessed in human peripheral blood mononuclear cells and primary macrophages. In an endotoxin-induced uveitis (EIU) study, lipopolysaccharide (LPS) was administered intravitreally to Lewis rats. TOP1362, dexamethasone, or vehicle was administered topically, and inflammatory cytokine levels were measured 6 hours after LPS injection. RESULTS: HCE cells from DED patients showed significantly increased expression of p38α, spleen tyrosine kinase (Syk), Src, lymphocyte-specific protein tyrosine kinase (Lck), interleukin one beta (IL-1β), interleukin eight (IL-8), monocyte chemotactic protein-1 (MCP-1), and matrix metalloproteinase-9 (MMP-9). TOP1362 strongly inhibited the kinase targets p38α, Syk, Src, and Lck, blocked the rise in p38α expression in hyperosmolar Chang cells, and potently reduced inflammatory cytokine release in cellular models of innate and adaptive immunities. In the EIU model, TOP1362 dose-dependently attenuated the LPS-induced rise in inflammatory cell infiltration and ocular cytokine levels with efficacy comparable to that of dexamethasone. CONCLUSIONS: TOP1362 is a potent inhibitor of kinases upregulated in DED and markedly attenuates proinflammatory cytokine release in vitro and in vivo, highlighting the therapeutic potential of NSKIs for treating ocular inflammation, such as that observed in DED.
引用
- Hagan S, Fyfe MCT, Ofori-Frimpong B, et al. Narrow Spectrum Kinase Inhibitors Demonstrate Promise for the Treatment of Dry Eye Disease and Other Ocular Inflammatory Disorders. Invest Ophthalmol Vis Sci. 2018. PMID: 29625466. doi:10.1167/iovs.17-23479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。